Current and future clinical utilities of Parkinson’s disease and dementia biomarkers: can they help us conquer the disease?

References

• Chahine LM, Stern MB, Chen-Plotkin A. Blood-based biomarkers for Parkinson's disease. Parkinsonism Relat Disord. 2014;20 Suppl 1(01):S99–S103.
   Google Scholar
• Nam GE, Kim SM, Han K, et al. Metabolic syndrome and risk of Parkinson disease: A nationwide cohort study. PLoS Med. 2018;15:e1002640.
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839–840.
   PubMed Web of Science ®Google Scholar
• Tokuda T, Salem SA, Allsop D, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. Biochem Biophys Res Commun. 2006;349:162–166.
   PubMed Web of Science ®Google Scholar
• El-Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. Faseb J. 2006;20:419–425.
   PubMed Web of Science ®Google Scholar
• Majbour NK, Vaikath NN, van Dijk KD, et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease. Mol Neurodegener. 2016;11:7.
   PubMed Web of Science ®Google Scholar
• El-Agnaf OM, Paleologou KE, Greer B, et al. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson’s disease and related disorders. Faseb J. 2004;18(11):1315–1317.
   PubMed Web of Science ®Google Scholar
• Pujols J, Pena-Diaz S, Lazaro DF, et al. Small molecule inhibits alpha-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons. Proc Natl Acad Sci U S A. 2018;115(41):10481–10486.
   PubMed Web of Science ®Google Scholar
• Kurnik M, Sahin C, Andersen CB, et al. Potent alpha-synuclein aggregation inhibitors, identified by high-throughput screening, mainly targeting the monomeric state. Cell Chem Biol. 2018;25(11):1389–1402 e1389.
   PubMed Web of Science ®Google Scholar
• Waragai M, Nakai M, Wei J, et al. Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson’s disease. Neurosci Lett. 2007;425(1):18–22.
   PubMed Web of Science ®Google Scholar
• Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet. 2005;365(9457):415–416.
   PubMed Web of Science ®Google Scholar
• Di Fonzo A, Rohe CF, Ferreira J, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson’s disease. Lancet. 2005;365(9457):412–415.
   PubMed Web of Science ®Google Scholar
• Wallings R, Manzoni C, Bandopadhyay R. Cellular processes associated with LRRK2 function and dysfunction. Febs J. 2015;282(15):2806–2826.
   PubMed Web of Science ®Google Scholar
• Zhu X, Babar A, Siedlak SL, et al. LRRK2 in Parkinson’s disease and dementia with Lewy bodies. Mol Neurodegener. 2006;1:17.
   PubMed Web of Science ®Google Scholar
• Smith WW, Pei Z, Jiang H, et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A. 2005;102(51):18676–18681.
   PubMed Web of Science ®Google Scholar
• MacLeod D, Dowman J, Hammond R, et al. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron. 2006;52(4):587–593.
   PubMed Web of Science ®Google Scholar
• Cook DA, Kannarkat GT, Cintron AF, et al. LRRK2 levels in immune cells are increased in Parkinson’s disease. NPJ Parkinsons Dis. 2017;3:11.
   PubMed Web of Science ®Google Scholar
• Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology. 1999;53(9):1937–1942.
   PubMed Web of Science ®Google Scholar
• Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia aging study. Diabetes. 2002;51(4):1256–1262.
   PubMed Web of Science ®Google Scholar
• Hu G, Jousilahti P, Bidel S, et al. Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care. 2007;30(4):842–847.
   PubMed Web of Science ®Google Scholar
• Cereda E, Barichella M, Pedrolli C, et al. Diabetes and risk of Parkinson’s disease: a systematic review and meta-analysis. Diabetes Care. 2011;34(12):2614–2623.
   PubMed Web of Science ®Google Scholar
• Cereda E, Barichella M, Cassani E, et al. Clinical features of Parkinson disease when onset of diabetes came first: A case-control study. Neurology. 2012;78(19):1507–1511.
   PubMed Web of Science ®Google Scholar
• Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122(4):1316–1338.
   PubMed Web of Science ®Google Scholar
• Singh P, Alex JM, Bast F. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer. Med Oncol. 2014;31(1):805.
   PubMed Web of Science ®Google Scholar
• Copps KD, White MF. Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia. 2012;55(10):2565–2582.
   PubMed Web of Science ®Google Scholar
• Gao S, Duan C, Gao G, et al. Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling. Int J Biochem Cell Biol. 2015;64:25–33.
   PubMed Web of Science ®Google Scholar
• Bassil F, Canron MH, Dutheil N, et al. Brain insulin resistance in Parkinson’s disease. Mov Disord. 2017;32(suppl 2).
   Web of Science ®Google Scholar
• Waragai M, Ho G, Takamatsu Y, et al. Importance of adiponectin activity in the pathogenesis of Alzheimer’s disease. Ann Clin Transl Neurol. 2017;4(8):591–600.
   PubMed Web of Science ®Google Scholar
• Holscher C. The role of GLP-1 in neuronal activity and neurodegeneration. Vitam Horm. 2010;84:331–354.
   PubMed Web of Science ®Google Scholar
• Chiu SL, Chen CM, Cline HT. Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron. 2008;58(5):708–719.
   PubMed Web of Science ®Google Scholar
• Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409–1439.
   PubMed Web of Science ®Google Scholar
• Yamaoka-Tojo M, Tojo T, Takahira N, et al. Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc Diabetol. 2010;9:17.
   PubMed Web of Science ®Google Scholar
• Holscher C, Li L. New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer’s disease? Neurobiol Aging. 2010;31(9):1495–1502.
   PubMed Web of Science ®Google Scholar
• Perry T, Lahiri DK, Chen D. et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Therap. 2002;300(3):958–966.
   PubMed Web of Science ®Google Scholar
• Perry T, Lahiri DK, Sambamurti K, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron. J Neurosci Res. 2003;72(5):603–612.
   PubMed Web of Science ®Google Scholar
• Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci. 2002;18(1–2):7–14.
   PubMed Web of Science ®Google Scholar
• Gault VA, Holscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol. 2008;587(1–3):112–117.
   PubMed Web of Science ®Google Scholar
• Li Y, Duffy KB, Ottinger MA, et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. J Alzheimers Dis. 2010;19(4):1205–1219.
   PubMed Web of Science ®Google Scholar
• Gengler S, McClean PL, McCurtin R, et al. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging. 2012;33(2):265–276.
   PubMed Web of Science ®Google Scholar
• Li Y, Perry T, Kindy MS, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA. 2009;106(4):1285–1290.
   PubMed Web of Science ®Google Scholar
• Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664–1675.
   PubMed Web of Science ®Google Scholar
• Mentlein R. Dipeptidyl-peptidase IV (CD26)–role in the inactivation of regulatory peptides. Regul Pept. 1999;85(1):9–24.
   PubMed Web of Science ®Google Scholar
• Havre PA, Abe M, Urasaki Y, et al. The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci. 2008;13:1634–1645.
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–2157.
   PubMed Web of Science ®Google Scholar
• Bis JC, DeCarli C, Smith AV, et al. Common variants at 12q14 and 12q24 are associated with hippocampal volume. Nat Genet. 2012;44(5):545–551.
   PubMed Web of Science ®Google Scholar
• Gault VA, Lennox R, Flatt PR. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline. Diabetes Obes Metab. 2015;17(4):403–413.
   PubMed Web of Science ®Google Scholar
• D’Amico M, Di Filippo C, Marfella R, et al. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice. Exp Gerontol. 2010;45(3):202–207.
   PubMed Web of Science ®Google Scholar
• Kosaraju J, Holsinger RMD, Guo L, et al. Linagliptin, a dipeptidyl peptidase-4 inhibitor, mitigates cognitive deficits and pathology in the 3xTg-AD mouse model of Alzheimer’s disease. Mol Neurobiol. 2017;54(8):6074–6084.
   PubMed Web of Science ®Google Scholar
• Svenningsson P, Wirdefeldt K, Yin L, et al. Reduced incidence of Parkinson’s disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study. Mov Disord. 2016;31(9):1422–1423.
   PubMed Web of Science ®Google Scholar
• Abdelsalam RM, Safar MM. Neuroprotective effects of vildagliptin in rat rotenone Parkinson’s disease model: role of RAGE-NFkappaB and Nrf2-antioxidant signaling pathways. J Neurochem. 2015;133(5):700–707.
   PubMed Web of Science ®Google Scholar
• Chen B, Zheng T, Qin L, et al. Strong association between plasma dipeptidyl peptidase-4 activity and impaired cognitive function in elderly population with normal glucose tolerance. Front Aging Neurosci. 2017;9:247.
   PubMed Web of Science ®Google Scholar
• Kiraly K, Kozsurek M, Lukacsi E, et al. Glial cell type-specific changes in spinal dipeptidyl peptidase 4 expression and effects of its inhibitors in inflammatory and neuropatic pain. Sci Rep. 2018;8(1):3490.
   PubMedGoogle Scholar
• Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423(6941):762–769.
   PubMed Web of Science ®Google Scholar
• Mao X, Kikani CK, Riojas RA, et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol. 2006;8(5):516–523.
   PubMed Web of Science ®Google Scholar
• Wang C, Mao X, Wang L, et al. Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1. J Biol Chem. 2007;282(11):7991–7996.
   PubMed Web of Science ®Google Scholar
• Ryu J, Galan AK, Xin X, et al. APPL1 potentiates insulin sensitivity by facilitating the binding of IRS1/2 to the insulin receptor. Cell Rep. 2014;7(4):1227–1238.
   PubMed Web of Science ®Google Scholar
• Fernandez-Monreal M, Sanchez-Castillo C, Esteban JA. APPL1 gates long-term potentiation through its plekstrin homology domain. J Cell Sci. 2016;129(14):2793–2803.
   PubMed Web of Science ®Google Scholar
• Sekiyama K, Waragai M, Akatsu H, et al. Disease-modifying effect of adiponectin in model of α-synucleinopathies. Ann Clin Transl Neurol. 2014;1(7):479–489.
   PubMed Web of Science ®Google Scholar
• Une K, Takei YA, Tomita N, et al. Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer’s disease. Eur J Neurol. 2011;18(7):1006–1009.
   PubMed Web of Science ®Google Scholar
• Cassani E, Grünewald A, Voges L, et al. Serum adiponectin levels in advanced-stage Parkinson’s disease patients. Parkinsons Dis. 2011;2011:624764.
   PubMedGoogle Scholar
• Rocha NP, Scalzo PL, Barbosa IG, et al. Circulating levels of adipokines in Parkinson’s disease. J Neurol Sci. 2014;339(1–2):64–68.
   PubMed Web of Science ®Google Scholar
• Waragai M, Adame A, Trinh I, et al. Possible involvement of Adiponectin, the anti-diabetes molecule, in the pathogenesis of Alzheimer’s disease. J Alzheimers Dis. 2016;52:1453–1459.
   PubMed Web of Science ®Google Scholar
• Waragai M, Ho G, Takamatsu Y, et al. Dual-therapy strategy for modification of adiponectin receptor signaling in aging-associated chronic diseases. Drug Discov Today. 2018;23(6):1305–1311.
   PubMed Web of Science ®Google Scholar
• Ma QL, Yang F, Rosario ER, et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci. 2009;29(28):9078–9089.
   PubMed Web of Science ®Google Scholar
• Cho HJ, Xie C, Cai H. AGE-induced neuronal cell death is enhanced in G2019S LRRK2 mutation with increased RAGE expression. Transl Neurodegener. 2018;7:1.
   PubMed Web of Science ®Google Scholar
• Ness D, Ren Z, Gardai S, et al. Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis. PLoS One. 2013;8(6):e66164.
   PubMed Web of Science ®Google Scholar
• Akundi RS, Zhi L, Bueler H. PINK1 enhances insulin-like growth factor-1-dependent Akt signaling and protection against apoptosis. Neurobiol Dis. 2012;45:469–478.
   PubMed Web of Science ®Google Scholar
• Soutar MPM, Kempthorne L, Miyakawa S, et al. Akt signalling selectively regulates PINK1 mitophagy in SHSY5Y cells and human iPSC-derived neurons. Sci Rep. 2018;8:8855.
   PubMed Web of Science ®Google Scholar
• Kelm-Nelson CA, Stevenson SA, Ciucci MR. Atp13a2 expression in the periaqueductal gray is decreased in the Pink1 -/- rat model of Parkinson disease. Neurosci Lett. 2016;621:75–82.
   PubMed Web of Science ®Google Scholar
• Dehay B, Martinez-Vicente M, Ramirez A, et al. Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove. Autophagy. 2012;8:1389–1391.
   PubMed Web of Science ®Google Scholar
• Tsunemi T, Hamada K, Krainc D. ATP13A2/PARK9 regulates secretion of exosomes and alpha-synuclein. J Neurosci. 2014;34:15281–15287.
   PubMed Web of Science ®Google Scholar
• Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(Suppl 1):S210–212.
   PubMed Web of Science ®Google Scholar
• Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14:388–405.
   PubMed Web of Science ®Google Scholar
• Codolo G, Plotegher N, Pozzobon T, et al. Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies. PLoS One. 2013;8:e55375.
   PubMed Web of Science ®Google Scholar
• Bamberger ME, Harris ME, McDonald DR, et al. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci. 2003;23:2665–2674.
   PubMed Web of Science ®Google Scholar
• Paresce DM, Ghosh RN, Maxfield FR. Microglial cells internalize aggregates of the Alzheimer’s disease amyloid beta-protein via a scavenger receptor. Neuron. 1996;17:553–565.
   PubMed Web of Science ®Google Scholar
• Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2010;11:155–161.
   PubMed Web of Science ®Google Scholar
• Kim B, Kim DH, Oh SH, et al. Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One. 2012;7:e34693.
   PubMed Web of Science ®Google Scholar
• Tran TA, Nguyen AD, Chang J, et al. Lipopolysaccharide and tumor necrosis factor regulate Parkin expression via nuclear factor-kappa B. PLoS One. 2011;6:e23660.
   PubMed Web of Science ®Google Scholar
• Kim J, Byun J-W, Choi I, et al. PINK1 deficiency enhances inflammatory cytokine release from acutely prepared brain slices. Exp Neurobiol. 2013;22:38–44.
   PubMedGoogle Scholar
• Dugan LL, Ali SS, Shekhtman G, et al. IL-6 mediated degeneration of forebrain GABAergic interneurons and cognitive impairment in aged mice through activation of neuronal NADPH oxidase. PLoS One. 2009;4:e5518.
   PubMed Web of Science ®Google Scholar
• Barroso E, Del Valle J, Porquet D, et al. Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARbeta/delta-null mice. Biochim Biophys Acta. 2013;1832:1241–1248.
   PubMed Web of Science ®Google Scholar
• McClean PL, Holscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease. Neuropharmacology. 2014;76(Pt):A:57–67.
   PubMedGoogle Scholar
• Wagner L, Klemann C, Stephan M, et al. Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins. Clin Exp Immunol. 2016;184:265–283.
   PubMed Web of Science ®Google Scholar
• Badshah H, Ali T, Kim MO. Osmotin attenuates LPS-induced neuroinflammation and memory impairments via the TLR4/NFkappaB signaling pathway. Sci Rep. 2016;6:24493.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson’s disease psychosis. Neuropsychopharmacology. 2010;35:881–892.
   PubMed Web of Science ®Google Scholar
• Alves G, Brønnick K, Aarsland D, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson’s disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry. 2010;81:1080–1086.
   PubMed Web of Science ®Google Scholar
• Schirinzi T, Sancesario GM, Di Lazzaro G, et al. CSF alpha-synuclein inversely correlates with non-motor symptoms in a cohort of PD patients. Parkinsonism Relat Disord. 2018;61:203–206.
   Web of Science ®Google Scholar
• Nichols WC, Pankratz N, Marek DK, et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology. 2009;72:310–316.
   PubMed Web of Science ®Google Scholar
• Brockmann K, Srulijes K, Hauser AK, et al. GBA-associated PD presents with nonmotor characteristics. Neurology. 2011;77:276–280.
   PubMed Web of Science ®Google Scholar
• Fujita M, Sugama S, Sekiyama K, et al. A beta-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain. Nat Commun. 2010;1:110.
   PubMed Web of Science ®Google Scholar
• Fujita M, Hagino Y, Takamatsu Y, et al. Early manifestation of depressive-like behavior in transgenic mice that express dementia with Lewy body-linked mutant beta-synuclein. Neuropsychopharmacol Rep. 2018;38:95–97.
   PubMedGoogle Scholar
• Kleinridders A, Cai W, Cappellucci L, et al. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc Natl Acad Sci U S A. 2015;112:3463–3468.
   PubMed Web of Science ®Google Scholar
• Johansson P, Åberg D, Johansson J-O, et al. Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer’s disease. Psychoneuroendocrinology. 2013;38:1729–1737.
   PubMed Web of Science ®Google Scholar
• Trueba-Saiz A, Cavada C, Fernandez AM, et al. Loss of serum IGF-I input to the brain as an early biomarker of disease onset in Alzheimer mice. Transl Psychiatry. 2013;3:e330.
   PubMed Web of Science ®Google Scholar
• Pellecchia MT, Santangelo G, Picillo M, et al. Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naive Parkinson’s disease. Eur J Neurol. 2014;21:802–807.
   PubMed Web of Science ®Google Scholar
• Oh DJ, Han JW, Min BJ, et al. Association of up-regulated plasma adiponectin with risk of incident depression in a community-dwelling elderly population. J Clin Psychiatry. 2018;79:3.
   Web of Science ®Google Scholar
• Furman JL, Soyombo A, Czysz AH, et al. Adiponectin moderates antidepressant treatment outcome in the combining medications to enhance depression outcomes randomized clinical trial. Pers Med Psychiatry. 2018;9–10:1–7.
   PubMedGoogle Scholar
• Anderberg RH, Richard JE, Hansson C, et al. GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. Psychoneuroendocrinology. 2016;65:54–66.
   PubMed Web of Science ®Google Scholar
• El Yacoubi M, Vaugeois J-M, Marguet D, et al. Behavioral characterization of CD26 deficient mice in animal tests of anxiety and antidepressant-like activity. Behav Brain Res. 2006;171:279–285.
   PubMed Web of Science ®Google Scholar
• Canneva F, Golub Y, Distler J, et al. DPP4-deficient congenic rats display blunted stress, improved fear extinction and increased central NPY. Psychoneuroendocrinology. 2015;53:195–206.
   PubMed Web of Science ®Google Scholar
• Kamble M, Gupta R, Rehan HS, et al. Neurobehavioral effects of liraglutide and sitagliptin in experimental models. Eur J Pharmacol. 2016;774:64–70.
   PubMed Web of Science ®Google Scholar
• Moulton CD, Pickup JC, Amiel SA, et al. Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: findings from the South London Diabetes (SOUL-D) study. Prim Care Diabetes. 2016;10:156–159.
   PubMed Web of Science ®Google Scholar
• Sekiyama K, Takamatsu Y, Waragai M, et al. Role of genomics in translational research for Parkinson’s disease. Biochem Biophys Res Commun. 2014;452:226–235.
   PubMed Web of Science ®Google Scholar
• Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat Genet. 2009;41:1303–1307.
   PubMed Web of Science ®Google Scholar
• Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet. 2009;41:1308–1312.
   PubMed Web of Science ®Google Scholar
• Chung SJ, Kim M-J, Kim J, et al. Association of type 2 diabetes GWAS loci and the risk of Parkinson’s and Alzheimer’s diseases. Parkinsonism Relat Disord. 2015;21:1435–1440.
   PubMed Web of Science ®Google Scholar
• Hao K, Di Narzo AF, Ho L, et al. Shared genetic etiology underlying Alzheimer’s disease and type 2 diabetes. Mol Aspects Med. 2015;43–44:66–76.
   PubMed Web of Science ®Google Scholar
• Gao L, Cui Z, Shen L, et al. Shared genetic etiology between type 2 diabetes and Alzheimer’s disease identified by bioinformatics analysis. J Alzheimers Dis. 2016;50:13–17.
   PubMed Web of Science ®Google Scholar
• Wang G, van der Walt JM, Mayhew G, et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet. 2008;82:283–289.
   PubMed Web of Science ®Google Scholar
• Junn E, Lee K-W, Jeong BS, et al. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci U S A. 2009;106:13052–13057.
   PubMed Web of Science ®Google Scholar
• Doxakis E. Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J Biol Chem. 2010;285:12726–12734.
   PubMed Web of Science ®Google Scholar
• Gehrke S, Imai Y, Sokol N, et al. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature. 2010;466:637–641.
   PubMed Web of Science ®Google Scholar
• Minones-Moyano E, Porta S, Escaramís G, et al. MicroRNA profiling of Parkinson’s disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet. 2011;20:3067–3078.
   PubMed Web of Science ®Google Scholar
• Goodall EF, Heath PR, Bandmann O, et al. Neuronal dark matter: the emerging role of microRNAs in neurodegeneration. Front Cell Neurosci. 2013;7:178.
   PubMed Web of Science ®Google Scholar
• Schonrock N, Humphreys DT, Preiss T, et al. Target gene repression mediated by miRNAs miR-181c and miR-9 both of which are down-regulated by amyloid-beta. J Mol Neurosci. 2012;46:324–335.
   PubMed Web of Science ®Google Scholar
• Harraz MM, Dawson TM, Dawson VL. MicroRNAs in Parkinson’s disease. J Chem Neuroanat. 2011;42:127–130.
   PubMed Web of Science ®Google Scholar
• Kim W, Lee Y, McKenna ND, et al. miR-126 contributes to Parkinson’s disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. Neurobiol Aging. 2014;35:1712–1721.
   PubMed Web of Science ®Google Scholar
• Nelson PT, Wang WX. MiR-107 is reduced in Alzheimer’s disease brain neocortex: validation study. J Alzheimers Dis. 2010;21:75–79.
   PubMed Web of Science ®Google Scholar
• Mushtaq G, Greig NH, Anwar F, et al. miRNAs as circulating biomarkers for Alzheimer’s disease and Parkinson’s disease. Med Chem. 2016;12:217–225.
   PubMed Web of Science ®Google Scholar
• Ding H, Huang Z, Chen M, et al. Identification of a panel of five serum miRNAs as a biomarker for Parkinson’s disease. Parkinsonism Relat Disord. 2016;22:68–73.
   PubMed Web of Science ®Google Scholar
• Leidinger P, Backes C, Deutscher S, et al. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 2013;14:R78.
   PubMed Web of Science ®Google Scholar
• Takamatsu Y, Ho G, Koike W, et al. Combined immunotherapy with “anti-insulin resistance” therapy as a novel therapeutic strategy against neurodegenerative diseases. NPJ Parkinsons Dis. 2017;3:4.
   PubMed Web of Science ®Google Scholar
• Maddalena A, Papassotiropoulos A, Müller-Tillmanns B, et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Arch Neurol. 2003;60:1202–1206.
   PubMedGoogle Scholar
• McCaffrey P. Trials of diabetes-related therapies: mainly a bust; 2018. [cited 20 Nov 2018]. Available from: <https://www.alzforum.org/news/conference-coverage/trials-diabetes-related-therapies-mainly-bust>
   Google Scholar